Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK)
Chengdu, CN
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.27% | +3.23% | -9.90% | +7.01% | -5.34% | +5.54% | +14.25% | +564.32% | +564.32% | +564.32% | +564.32% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 15 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+6.5% ★ Q4'25: +1,436.5% (vs Q4'24)
-
EPS growth Biotechnology: +29.7%-38.3% Q4'25: -194.7% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-23.0% Q4'25: +9.8% (vs Q4'24)
-
EBIT margin Biotechnology: +0.0%-17.0% Q4'25: -20.1% (vs Q4'24)
-
ROIC Biotechnology: -16.1%-88.3% Q4'25: -125.2% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+4.0% Q4'25: +4.5% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.35× Q4'25: -0.20× (vs Q4'24)
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 10 EPS Ana. |
Dec 2027 17 Rev. Ana. 10 EPS Ana. |
Dec 2028 15 Rev. Ana. 14 EPS Ana. |
Dec 2029 11 Rev. Ana. 8 EPS Ana. |
Dec 2030 7 Rev. Ana. 12 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.93B
est: 1.88B (+3.0%)
|
2.06B
est: 2.18B (-5.5%)
|
3.13B
2.32B – 4.29B
+43.8% YoY
|
5.21B
3.13B – 6.69B
+66.3% YoY
|
7.77B
5.09B – 10.24B
+49.3% YoY
|
12.08B
7.91B – 15.92B
+55.5% YoY
|
16.87B
11.04B – 22.23B
+39.6% YoY
|
| EBITDA |
-47.36M
est: -668.84M (+92.9%)
|
-249.23M
est: -776.25M (+67.9%)
|
-1.12B
-1.53B – -828.46M
-43.8% YoY
|
-1.86B
-2.39B – -1.12B
-66.3% YoY
|
-2.77B
-3.65B – -1.81B
-49.3% YoY
|
-4.31B
-5.68B – -2.82B
-55.5% YoY
|
-6.01B
-7.92B – -3.94B
-39.6% YoY
|
| EBIT |
-138.75M
est: -754.61M (+81.6%)
|
-349.62M
est: -875.79M (+60.1%)
|
-1.26B
-1.73B – -934.70M
-43.8% YoY
|
-2.09B
-2.69B – -1.26B
-66.3% YoY
|
-3.13B
-4.12B – -2.05B
-49.3% YoY
|
-4.86B
-6.40B – -3.18B
-55.5% YoY
|
-6.78B
-8.94B – -4.44B
-39.6% YoY
|
| Net Income |
-266.77M
est: -342.95M (+22.2%)
|
-381.97M
est: -381.97M (+0.0%)
|
-196.92M
-628.57M – 509.04M
+48.4% YoY
|
631.09M
452.09M – 954.85M
+420.5% YoY
|
1.75B
742.12M – 3.59B
+176.9% YoY
|
3.17B
1.75B – 4.49B
+81.7% YoY
|
5.76B
3.17B – 8.14B
+81.4% YoY
|
| SGA |
129.23M
est: 954.23M (-86.5%)
|
284.72M
est: 1.11B (-74.3%)
|
1.59B
1.18B – 2.18B
+43.8% YoY
|
2.65B
1.59B – 3.40B
+66.3% YoY
|
3.95B
2.59B – 5.21B
+49.3% YoY
|
6.15B
4.02B – 8.10B
+55.5% YoY
|
8.58B
5.61B – 11.31B
+39.6% YoY
|
| EPS |
-1.20
est: -1.49 (+19.3%)
|
-1.66
est: -2.54 (+34.6%)
|
-1.04
-2.73 – 2.21
+59.1% YoY
|
2.95
1.96 – 4.14
+384.4% YoY
|
8.09
3.22 – 15.56
+174.0% YoY
|
13.77
7.58 – 19.46
+70.1% YoY
|
24.98
13.75 – 35.29
+81.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-10 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-09 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-03 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-02 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Matthews China Discovery Active ETF MCHS MCHS | 2.20% | 494.1K | 0.99% |
| 2 | Global X China Biotech ETF (HKD) 2820.HK | 2.09% | 1.67M | 0.68% |
| 3 | KraneShares MSCI All China Health Care Index ETF KURE | 2.05% | 1.63M | 0.79% |
| 4 | First Trust International Equity Opportunities ETF FPXI | 1.68% | 5.15M | 0.70% |
| 5 | Matthews Asia Innovators Active ETF MINV | 1.43% | 2.46M | 0.79% |
| 6 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.50% | 5.76M | 0.40% |
| 7 | iShares Ageing Population UCITS ETF AGED.L | 0.38% | 3.39M | 0.40% |
| 8 | UBS Solactive China Technology UCITS ETF USD acc CQQQ.SW | 0.36% | 1.34M | 0.47% |
| 9 | UBS Solactive China Technology UCITS ETF hEUR acc CITE.MI | 0.36% | 1.33M | 0.50% |
| 10 | UBS MSCI China Universal UCITS ETF USD dis CNSG.L | 0.24% | 558.9K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Junyou Ge | President, CEO, COO, GM & Executive Director | 10M | — |
| Ming Fai Chung | Joint Company Secretary | — | male |
| Nan Chao Ding | Deputy GM & Chief Marketing Officer | — | male |
| Wei Chen | Deputy General Manager | — | male |
| Wensheng Yu | Deputy General Manager & Chief Science Officer of Small Molecule | — | — |
| Xiangyang Tan | Deputy GM & Chief Scientific Officer of Large Molecule | — | — |
| Xiaoping Jin | Deputy GM & Chief Medical Officer | — | — |
| Yi Feng | Deputy GM, Chief Strategy Officer & Senior VP | — | male |
| Zejian Zhou | CFO & Joint Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6990.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
